Extra-abdominal cytoreductive techniques in ovarian cancer: how far can (should) we go?

被引:0
|
作者
Kahn, Ryan M. [1 ]
Chang, Suk-Joon [2 ]
Chi, Dennis S. [1 ,3 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY USA
[2] Ajou Univ, Sch Med, Obstet & Gynecol, Suwon, South Korea
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY 10065 USA
基金
美国国家卫生研究院;
关键词
Gynecologic Surgical Procedures; Ovarian Cancer; Surgical Oncology; Cytoreduction surgical procedures; CARDIOPHRENIC LYMPH-NODE; ASSISTED THORACIC-SURGERY; INGUINAL LYMPHADENOPATHY; SURGICAL CYTOREDUCTION; INTRATHORACIC SURGERY; RESIDUAL DISEASE; METASTASIS; SURVIVAL; CARCINOMA; MANAGEMENT;
D O I
10.1136/ijgc-2023-004630
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Complex surgery is an essential component in the management of advanced ovarian cancer. Furthermore, achieving complete gross resection in cytoreductive surgery appears to be associated with significant survival benefits in patients with advanced ovarian cancer. The goal of this review is to demonstrate the advancement of surgical techniques in gynecologic oncology surgery, including resection of disease within the intrathoracic and inguinal regions. This progress has expanded the option of surgery to more patients, especially those who would have previously been deemed inoperable. In this review we describe the most notable studies and reports of surgical resection of ovarian cancer involving cardiophrenic/supradiaphragmatic lymph nodes, mediastinum, lung pleura or parenchyma, and the inguinal region. We also describe the growing role that video-assisted thoracic surgery has played in advanced ovarian cancer diagnosis and management. The studies, series, and reports described demonstrate that comprehensive surgical procedures outside of the abdomen or pelvis can be both safe and feasible in properly selected patients. They also suggest that resection of disease outside of the abdomen or pelvis may benefit appropriately selected patients. Future studies are necessary to identify which patients may benefit most from upfront surgery versus neoadjuvant chemotherapy when ovarian cancer metastasis is present in the thoracic or inguinal regions.
引用
收藏
页码:379 / 385
页数:7
相关论文
共 50 条
  • [1] How far should we go in optimal cytoreductive surgery for ovarian cancer?
    Hernandez-Lopez, Luis A.
    Elizalde-Mendez, Angel
    [J]. CHINESE CLINICAL ONCOLOGY, 2020, 9 (05)
  • [2] HOW FAR SHOULD WE GO
    MARK, JBD
    [J]. ANNALS OF THORACIC SURGERY, 1988, 46 (01): : 3 - 3
  • [3] HOW FAR SHOULD WE GO
    VINES, G
    [J]. NEW SCIENTIST, 1994, 141 (1912) : 12 - 13
  • [4] HOW FAR SHOULD WE GO
    THOMAS, D
    [J]. BRITISH DENTAL JOURNAL, 1988, 164 (03) : 65 - 65
  • [5] How far should we go in treating cancer patients?
    Klastersky, J
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1006 - 1006
  • [6] Centralization of esophagectomy for cancer: How far should we go?
    Dikken, J. L.
    Henneman, D.
    Putter, H.
    Lemmens, V. E. P. P.
    Van der Geest, L. G.
    Van Hillegersberg, R.
    Van de Velde, C. J. H.
    Wouters, M. W. J. M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S576 - S576
  • [7] SBRT for metastatic disease: how far can and should we go?
    Dahele, M.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S190 - S190
  • [8] Sedation in the emergency department: how far can and should we go?
    Cheron, G.
    Brissaud, O.
    Wille, C.
    Chappuy, H.
    [J]. ARCHIVES DE PEDIATRIE, 2007, 14 (06): : 732 - 734
  • [9] How far can we go?
    Lewis, Dan
    [J]. POWER ENGINEER, 2007, 21 (01): : 12 - 15
  • [10] HOW FAR CAN WE GO?
    Kim, Sung Hong
    Maas, Winy
    [J]. SPACE, 2016, (584): : 64 - 67